It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics ...
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results